These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15230666)

  • 1. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice.
    Cadahia V; García-Carbonero A; Vivas S; Fuentes D; Niño P; Rebollo P; Rodrigo L
    Rev Esp Enferm Dig; 2004 Jun; 96(6):369-74; 374-8. PubMed ID: 15230666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
    Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
    N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
    Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
    Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
    N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
    Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
    Lichtenstein GR; Yan S; Bala M; Blank M; Sands BE
    Gastroenterology; 2005 Apr; 128(4):862-9. PubMed ID: 15825070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
    Rodrigo L; Pérez-Pariente JM; Fuentes D; Cadahia V; García-Carbonero A; Niño P; de Francisco R; Tojo R; Moreno M; González-Ballina E
    Rev Esp Enferm Dig; 2004 Aug; 96(8):548-54; 554-8. PubMed ID: 15449986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
    Sands BE; Blank MA; Patel K; van Deventer SJ;
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):912-20. PubMed ID: 15476155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
    Poritz LS; Rowe WA; Koltun WA
    Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA
    Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.